Search the Newsreel

Is Immunic Inc (IMUX) Struggling After Recent Earnings? EPS Misses Estimates with GF Score: 32/100

Immunic: Q2 Earnings Snapshot

This article provides an earnings snapshot for Immunic's Q2 performance. Due to the limited content provided, specific details regarding financial figures or company performance are not available.

Immunic (IMUX) Earnings Date and Reports 2026

Immunic (IMUX) announced its Q2 2026 earnings on August 11, 2026, reporting an EPS of -$0.80, which surpassed analysts' consensus estimates of -$1.16 by $0.36. The company's earnings are projected to improve from -$4.41 to -$4.05 per share next year. The article provides detailed …

Form 8K Immunic Inc For: 11 August By Investing.com

The article is a brief announcement indicating that Immunic Inc. filed a Form 8K on August 11. It mentions the company's stock symbol IMUX and its price performance, but provides no further details about the content of the filing. The rest of the page …

Immunic (NASDAQ:IMUX) Issues Quarterly Earnings Results, Beats Estimates By $0.36 EPS

Immunic (NASDAQ:IMUX) reported its quarterly earnings, beating analyst estimates by $0.36 EPS with a reported ($0.80) earnings per share. The company's stock opened at $14.62, with a market capitalization of approximately $199 million, and has seen significant institutional investment. Wall Street analysts maintain a …

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic advances MS drug toward key Phase 3 data, expects results by year-end Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones as it advances its lead drug candidate vidofludimus calcium through late-stage …

Immunic Inc (IMUX) Q2 Earnings Beat Highlights Growth Potential Despite Unprofitability

Immunic CEO on Q2 progress and Phase 3 MS trial milestones

Immunic CEO Erik Lundgren discussed the company's Q2 results, leadership changes, and key milestones for its multiple sclerosis (MS) program. The company's two Phase 3 studies for relapsing MS are fully enrolled and expected to report results by year-end, with Immunic also planning to …

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic (IMUX) director Elena Ridloff receives 50,740 stock options at $14.54

Immunic (IMUX) director Elena Ridloff was granted 50,740 stock options on August 6, 2026, with an exercise price of $14.54 per share. These options, which vest monthly over three years and expire on August 6, 2036, significantly increase her direct holdings. The transaction was …

Immunic appoints Elena Ridloff to board of directors By Investing.com

Immunic, Inc. has appointed Elena Ridloff to its board of directors, effective Wednesday. Ridloff brings over 20 years of experience in finance, corporate development, and capital markets within the biopharmaceutical industry. Immunic is a late-stage biotechnology company developing oral therapies for neurologic diseases and …

Laurion Capital discloses 6.06% Immunic (IMUX) stake via shares and warrants

Laurion Capital Management LP and its related entities have disclosed a 6.06% beneficial ownership stake in Immunic, Inc. (IMUX) as of June 30, 2026. This stake comprises 839,526 shares, including common stock and shares issuable upon the exercise of warrants. The filing indicates shared …

IMUX Technical Analysis & ETF Price Forecast

The article provides a technical analysis of Immunic, Inc. (IMUX), indicating a "Neutral" sentiment based on various technical indicators. While some moving averages suggest a "Buy" signal given the current share price of $14.05, momentum indicators like RSI and MACD are currently neutral. The …

OMERS ADMINISTRATION Corp Makes New Investment in Immunic, Inc. $IMUX

OMERS ADMINISTRATION Corp recently invested in Immunic, Inc. (NASDAQ:IMUX) by acquiring 168,300 shares valued at approximately $187,000, representing about 1.24% of the company. Despite a recent earnings miss, analysts maintain a "Buy" consensus rating with an average price target of $47.57. Immunic, a biopharmaceutical …

Immunic Inc (IMUX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Immunic Inc (IMUX) based on TradingKey's assessment. It highlights the company's current financial score of 7.02, ranking 166 out of 385 in the Biotechnology & Medical Research industry, indicating a robust financial status but low operating …

IMUX|Immunic Inc|Price:13.271|Chg%:-0.539

This article provides a detailed stock analysis of Immunic Inc (IMUX) based on TradingKey's comprehensive stock score. It highlights Immunic's strong fundamentals and high growth potential, noting it's fairly valued within the Biotechnology & Medical Research industry. The analysis also covers high institutional ownership …

Immunic Inc (IMUX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Immunic Inc (IMUX), noting its current valuation score of 9.22, which ranks 48 out of 386 in its industry. The company's P/E ratio is reported as -0.95, significantly differing from its recent high and low. Data for …

Press Release: Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

Immunic, Inc. has appointed Michael W. Bonney as Chair of its Board of Directors. Bonney brings extensive experience from his previous leadership roles at Kaleido Biosciences, Baxalta Inc., and Cubist Pharmaceuticals, as well as his current positions on the boards of several prominent biotechnology …

Immunic Inc (IMUX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Immunic Inc (IMUX). It states that the company has not distributed any dividends in the past five years. However, it lists a significant 10-for-1 merger type stock split scheduled for April 14, 2026.

Immunic Inc (IMUX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Immunic Inc (IMUX), detailing various financial metrics related to volatility, maximum drawdown, and liquidity. Key figures include a Beta vs S&P 500 index of 1.35, a 240-Day Volatility of +95.96%, and a 5-year maximum drawdown of +96.42%. …

Immunic Inc (IMUX) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Immunic Inc (IMUX), including sections on operating, investing, and financing cash flows. It also offers a FAQ section defining these terms and providing specific cash flow figures for Immunic Inc, such as …

Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from Analysts

Immunic, Inc. (NASDAQ:IMUX) has received an average "Buy" rating from eleven analysts, with a consensus 12-month price target of $47.57. This comes despite the company reporting a quarterly loss of ($1.08) per share, missing analyst expectations. Institutional investors have been actively trading Immunic shares, …

Immunic, Inc. Revenue Breakdown – NASDAQ:IMUX

This page provides access to financial information for Immunic, Inc. (NASDAQ: IMUX) on TradingView. Users can view financials, including revenue breakdowns by source and country. The content highlights various data providers and copyright notices.

abrdn discloses 6.05% Immunic (IMUX) stake held for clients

abrdn Group plc and its subsidiary abrdn Inc. have disclosed a beneficial ownership of 824,393 shares of Immunic, Inc. (IMUX) common stock, representing 6.05% of the outstanding class. This ownership is held on behalf of their clients, with shared voting and dispositive power. The …